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INTRODUCTION
Stroke is caused by occlusion of or hemorrhage from a blood 
vessel supplying the brain. It is a cause of long-term disability and 
ranks as the third frequent cause of death following heart disease 
and cancer, yet despite high prevalence, the number of approved 
therapies remains low [1, 2]. The major therapeutic strategy for 
treatment of acute ischemic stroke is rapid recanalization, either by 
pharmacological means through thrombolytic agents, or mechani-
cal thrombectomy [3]. However, the time window for intervention 
limits these therapies to a small number of patients, and their inap-
propriate use can actually worsen outcome.
Stroke, via occlusion of cerebral artery(ies) brings on energy de-
pletion and subsequent death of cells in the vascular territory. Cur-
rently, understanding of the pathophysiology of ischemic stroke 
indicates that the mechanism of neuronal injury can be character-
ized according to infarct progression over time. The acute stage 
appears within minutes up to a few hours after ischemic stroke 
onset, during which ionic homeostasis is disrupted by the decrease 
in cerebral blood flow. This phenomenon leads to increased in-
tracellular calcium concentrations and stimulation of glutamate 
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release, producing excitotoxicity and a spreading depression 
throughout the ischemic region [4-6]. Water enters the intracel-
lular space due to osmotic gradients, causing cells swell, and the 
resulting vasogenic edema can give rise to intracranial pressure, 
vascular compression and herniation [5]. Furthermore, the gen-
eration of reactive oxygen species (ROS) can destroy membranes, 
mitochondria and DNA, leading to proteins misfolding and en-
zyme dysfunction. These factors are exacerbated in the event of 
reperfusion takes place. In the second-subacute phase occurs a few 
hours to a few days after ischemia. An inflammatory and cell death 
(apoptosis and necrosis) response develops as a result of the stimu-
latory influences of the acute phase [4, 5, 7]. In additional to these 
responses, high intracellular calcium concentrations built up dur-
ing the acute phase lead to the overactivation of several proteolytic 
enzyme systems.
Recent studies have focused on the role of superoxide generating 
systems in immune cells and their consequences on reperfusion 
injury (RI), or that injury which results when the occluded vessel is 
reopened. Of the various systems by which cells can generate reac-
tive oxygen species (ROS), the topic of this review will focus on 
superoxide produced by activation of the NADPH oxidase (NOX). 
Superoxide is soluble in solution and can combine with other 
ROS to form more toxic molecules after experimental ischemic 
stroke [8]. The importance of NOX in production of ROS and 
subsequent neuronal cell death has been the subject of somewhat 
recent investigations. Several other enzymes found throughout the 
cell are involved in ROS generation, including xanthine oxidase, 
lipoxygenase, cylcoocxygenases (COX) and substrate coupled 
nitric oxide synthetase, but none of these can produce the large 
amount of ROS observed in nonphagocytic cells in both normal 
and pathological conditions [9]. In the last decade, study into the 
NOX enzyme has made a major new turn with discovery of a large 
number of NOX homologs which may allow for a more targeted 
therapeutic approach. At present, no specific treatments exist for 
NOX induced ROS in central nervous system (CNS) diseases and 
most of these diseases have very few therapeutic options at all. This 
will be discussed in more detail in this review.
NADPH OXIDASE (NOX)
Oxidative stress leads to overload of ROS caused by excessive 
ROS production and/or impaired ROS reduction. Under condi-
tions of oxidative stress, the overproduction of ROS becomes 
detrimental and possibly contributes to various acute and chronic 
diseases, such as myocardial infarction, hypertension, atheroscle-
rosis, cancer, neurodegeneration, and inflammation. Consequently, 
oxidative stress has also been suggested as an important underly-
ing mechanism of ischemic stroke [10].
Among many enzymes utilizing molecular oxygen as substrate, 
NOX is activated and can serve as a source of ROS in the CNS 
[11]. Seven NOX family members have been identified and iso-
forms are denoted as NOX1 to NOX5, dual oxidase (Duox)-1 
and -2. NOX1, 2 and 4 have been detected in the CNS, with cells 
such as neurons and intracranial vessels as well as microglia [12, 
13]. NOX3 is almost exclusively expressed in the inner ear but not 
in blood vessels. Gene deletion of NOX5 in the rodent genome 
is the least functionally characterized isoform compared to oth-
ers [14]. Nevertheless, several recent studies show that NOX5 is 
activated by calcium in human cells. Thus, it may be a key player 
in ROS generation in vascular cells [15, 16]. Duox-1 and -2, also 
contain an oxidase domain, which appear to be expressed pre-
dominantly in epithelial cells [17]. Recently, in vitro studies have 
shown NOX expression in neurons, astrocytes, and microglia [11]. 
In vivo studies have also shown that NOX subunits are widely 
distributed in the cortex, the hippocampus, and in the cerebel-
lum [13, 18]. NOX is a multi-component enzyme comprising of 
cytoplasmic (p47phox, p67phox, p40phox and Rac) and membrane 
bound (p91phox and p22phox) subunits. Upon phosphorylation by 
specific protein kinases, these cytoplasmic subunits can form a 
complex and translocate to the plasma membrane to dock with 
the plasma membrane subunits [19]. Catalysis of NOX occurs in 
the p91phox subunit, which begins the transfer of electrons from 
molecular oxygen through redox coupling with NADPH, FAD 
and heme to generate superoxide [20] (Fig. 1). During activation, 
the p47phox component is phosphorylated and moves to the plasma 
membrane, where it assembles with the other subunits to generate 
an active enzyme complex. It produces superoxide by transferring 
electrons from NADPH inside the cell across the membrane and 
coupling these to molecular oxygen to produce superoxide. Super-
oxide can also be generated within phagosomes. Within phago-
somes, superoxide can spontaneously form hydrogen peroxide, 
which is also a reactive species [20]. Vascular ROS are produced in 
endothelial, adventitial, and vascular smooth muscle (VSMC) and 
derived primarily from NOX, a multisubunit enzyme catalyzing 
a superoxide anion (O2
●–) production by the 1 electron reduction 
of oxygen using NOX as the electron donor: 2O2+NADPH → 
2O2
-+NADP+H+ [21]. Superoxide is capable of killing bacteria 
and fungi by mechanisms that are not yet fully understood, but 
may inactivate critical metabolic enzymes, initiate lipid peroxida-
tion and liberate redox active iron, which allows the generation of 
indiscriminate oxidants such as the hydroxyl radical. Superoxide 
probably kills bacteria directly as the virulence of many pathogens 
is dramatically attenuated when their superoxide dismutase (SOD) 
genes are deleted. However, downstream products of superoxide 
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also include hydrogen peroxide and hypochlorous acid, the reac-
tive agent in bleach. NOX activation depends on phosphorylation, 
especially of the p47phox subunit [22]. While other subunits can 
be phosphorylated, p47phox phosphorylation appears a key player 
in the membrane translocation of other subunits as well. Kinases 
known to phosphorylate p47 include several of protein kinase C 
isoforms (β, δ and ζ) as well as p38 and p21 mitogen activated ki-
nases (MAPK) and protein kinase B. Further, it appears that NOX 
can be regulated by the inflammatory transcription factor, nuclear 
factor kappa B (NFκB). NFκB can induce gp91phox expression, 
as cells deficient in NFκB’s p65 subunit express less gp91phox in 
response to lipopolysaccharide (LPS) stimulation [6].
FUNCTION OF NOX IN REPERFUSION INJURY (RI) AFTER 
ISCHEMIC STROKE
NOX isoforms have been reported in the brain and its vascu-
lature. Thus, cerebrovascular disease may benefit from NOX as 
a therapeutic target in the brain, as well as in its blood vessels. 
Recently, NOX may be a key player in the prevention of RI, an 
increasingly observed complication of delayed recanalization 
leading to brain edema or hemorrhage [23, 24]. Thus, therapies to 
minimize RI might expand populations of stroke patients eligible 
for treatment. RI begins after ischemic stroke when the brain is 
quickly exposed to oxygenated blood, and ischemic mitochondria 
within the brain are rendered incapable of detoxifying reactive 
species [10].
A robust inflammatory reaction characterized by peripheral leu-
kocyte influx into the cerebral parenchyma and activation of en-
dogenous microglia follows ischemic stroke. While immune cells 
generate ROS through several enzyme systems, NOX is the major 
enzyme that generates superoxide in these cells. ROS elaborated 
by these cells can then activate other cells, even ischemic neurons, 
to secrete inflammatory factors. How NOX is activated in stroke 
is not entirely clear, but phosphorylation of the 47phox subunit ap-
pears key. This phosphorylation can occur through several kinases 
also upregulated and activated by brain ischemia, including several 
protein kinase C isoforms and the p38 and p21 been described 
[25], phagocytic NOX, also referred to as NOX2, is associated with 
immune cells. While NOX2 has been described in various cell 
types, NOX2 expression is greatest in myeloid cells [26], which, 
in the case of brain, are microglia [27]. A previous study showed 
that microglial cells isolated from the human fetal brain expressed 
Nox2, p22phox, p40phox, p47phox, and p67phox transcripts [28]. 
A large number of studies also demonstrated superoxide generat-
ing NOX systems in immune cells and their consequences on RI. 
Thus, inhibition of NOX can potentially reduce the amount of 
superoxide generated, and thus limit RI. This approach has the 
potential to not only treat acute ischemic stroke, but also reduce 
complications of recanalizing strategies by using it in combination 
with thrombolytics or mechanical thrombectomy devices.
NOX expression has been shown to increase in the brain after 
experimental stroke [29, 30], and several groups have shown that 
mice deficient in the gp91phox subunit had smaller infarcts than 
wildtype mice [8, 31-34]. Further, NOX appears to play a signifi-
cant role in RI. While RI has been attributed to the restoration of 
blood oxygen leading to a surge in ROS, some studies indicate that 
the source of damaging ROS may, in fact, be due to the return of 
blood glucose, which then fuels NOX to generate more ROS. In 
this case, NOX serves as an electron donor to produce damaging 
levels of superoxide, and NOX activation is dependent on glucose 
[35]. NOX also appears to be a primary source of ROS generated 
Fig. 1. NADPH oxidase (NOX) activation. 
NOX comprises cytosolic (p47phox, p67 
phox, p40 phox and Rac) and membrane 
subunits (gp91 phox and p22 phox). During 
activation of NOX, cytosolic subunits com-
prise a multi-component enzyme and mi-
grate to the plasma membrane to dock with 
the membrane subunits. This multisubunit 
enzyme produces a superoxide anion (O2
●–).
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by NMDA receptor activation, thus suggesting another mecha-
nism of ROS generation [36]. 
The targeting of NOX does not need to be restricted to the brain 
itself. While NOX and its isoforms are certainly present in microg-
lia and other brain cell types, NOX present on circulating leuko-
cytes contributes substantially to stroke pathology [32]. In a prior 
study by our lab, the use of bone marrow chimeras allowed us to 
replace marrow derived cells lacking functional NOX2 into wild-
type mice, and vice versa, replacing marrow with intact NOX2 into 
NOX2 deficient mice. After subjecting these chimeras to strokes, 
mice lacking circulating NOX2 but intact brain NOX2 had better 
outcomes compared to mice with intact circulating NOX2, but 
deficient brain NOX2. Vascular NOX is another relevant target. 
Aged mice have been found to have dysregulated cerebrovascular 
responses compared to similar aged mice deficient in NOX [37]. 
Vascular NOX also appears to contribute to cerebrovascular dys-
function and behavioral deficits in models of Alzheimer’s disease 
[38, 39]. Thus, the development of NOX inhibiting compounds 
may not necessary have to penetrate the blood brain barrier (BBB) 
in order to be effective against stroke and related conditions.
PHARMACOLOGICAL COMPOUNDS TO INHIBIT NOX ENZYMES
Several pharmacological compounds have been studied to target 
NOX enzymes in ischemic stroke. However, these are generally 
very low in specificity and selectivity. There has not been much 
clinical development since many are associated with toxicities that 
could hinder their use in humans. Yet, safer and more specific in-
hibitors are under development.
Diphenyleneiodonium (DPI)
DPI has been shown to protect the brain from stroke by blocking 
NOX [40]. It impairs NOX via flavoprotein inhibition to prevent 
superoxide production. Intravenous DPI administration reduced 
magnetic resonance imaging detected ischemic lesion size in an 
experimental stroke model suggesting that it is capable of pen-
etrating the BBB. Further, it was shown to decrease expression of 
extracellular matrix proteins MMP-2 and MMP-9, proteins known 
to contribute to BBB disruption [40]. In a hypoxia model, DPI also 
improved the integrity of tight-junctions in the BBB by reducing 
ROS production [41]. DPI treatment has also been associated with 
the inhibition of the inflammatory response accompanying stroke 
[42]. However, DPI’s usefulness is limited because it can also in-
hibit other flavoenzymes in vivo [31]. Flavoenzymes play a crucial 
role in many metabolic pathways. 
Apocynin
Perhaps the most widely NOX inhibitor in experimental stroke 
is apocynin, also known as acetovanillone. Apocynin is a naturally 
occurring organic compound, originally derived from the root of 
Canadian hemp (Apocynum cannabinum ) and Picrorhiza kur-
roa, a medicinal herb that has been used for centuries by the Chi-
nese and South Asians to treat inflammatory diseases [43, 44]. Its 
chemical name is 4-hydroxy-3-methoxy-acetophenone, and it is a 
methoxy-substituted catechol which was Apocynin is a commonly 
used anti-oxidant and anti-inflammatory capability, specifically, 
for blocking the activity of NOX in many experiment models 
involving phagocytic and nonphagocytic cells [45, 46]. It also ap-
proached to NOX inhibitor with relatively low affinity (IC50: ~10 
μmol/l) in neutrophils [47]. It does not seem to interfere with other 
polymorphonuclear neutrophil defense mechanisms, as it does not 
affect phagocytosis or intracellular killing [48]. Apocynin inhibits 
the release of superoxide through NOX by blocking migration 
of p47phox to the membrane, thus interfering with assembly of the 
functional NOX complex [49]. The inhibitory action of the com-
pound, however, occurs after a lag time only. Some of its inhibitory 
activity at least initially may involve myeloperoxidase (MPO) be-
cause apocynin does not inhibit NOX or the generation of super-
oxide in cells devoid or deficient in MPO [48, 50]. MPO together 
with hydrogen peroxide can facilitate apocynin dimerization, and 
these dimers can prevent assembly of an active enzyme complex 
(Fig. 2). Furthermore, agents such as zymosan that promote the 
Fig. 2. Mechanism of NOX inhibition by apocynin. Apocynin dimeriza-
tion by myeloperoxidase (MPO) and hydrogen peroxide (H2O2).
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release of MPO also enhance the efficacy of apocynin [47, 48]. In 
cells with less MPO, apocynin can reduce oxidant stress through a 
non-specific oxidative scavenger effect instead of NOX inhibition 
[50]. However, besides MPO, other peroxidases, such as horserad-
ish peroxidase, can also induce apocynin dimer formation with a 
consequent NOX inhibitory effect [49, 51]. Recent study showed 
that MPO secreted by neutrophils can be taken up by endothelial 
cells, in which apocynin can then be metabolized to active dimers, 
thus inhibiting vascular NOX in vivo [51] (Fig. 3). In line with this 
concept, it was observed that supplementation with thiol provided 
either as glutathione or cysteine prevents the inhibitory effect of 
apocynin on the NOX. Apocynin dimer formation may be respon-
sible for its delayed inhibitory property [52]. It has been suggested 
that this dimer is what blocks NOX activity [53]. 
The effect of apocynin has been widely explored in experimental 
ischemic stroke. It has also been documented to penetrate into the 
brain following systemic delivery [54], and several groups have 
shown the salutary effects of treatment on lesion size, brain hem-
orrhage reduction and improvements in neurological deficits. Pre-
vious our lab reported that a dose of 2.5 mg/kg given just prior to 
reperfusion, or 1.5 hours after ischemic stroke, resulted in reduced 
infarct size and improved neurological outcome while markedly 
suppressing superoxide generation in the brain [54]. However, 
at higher doses (3.75 and 5 mg/kg), apocynin showed no benefit, 
and actually increased the severity of brain hemorrhage. Thus, this 
rather narrow therapeutic dose range may limit its translation to 
the clinical level. However, other groups have shown salutary ef-
fects of apocynin at doses as high as 40~50 mg/kg [31, 55], while 
another group found no effect of apocynin using a dose of about 4 
mg/kg [56]. In global cerebral ischemia, 5 mg/kg apocynin attenu-
ated hippocampal injury when given prior to ischemia onset [57]. 
In safety studies of uninjured mice, apocynin was well tolerated in 
single oral doses of up to 1000 mg/kg [58]. Interestingly, apocynin 
failed to have any further beneficial effect in NOX2 deficient mice 
subjected to stroke, and might speak somewhat to its specificity or 
its dependence on NOX2 [32]. In addition to apocynin, Altered 
NOX function has been linked to neurological disorders such as 
Alzheimer’s (ALS) and Parkinson’s diseases (PD) [59]. Apocynin 
has been effective in ameliorating neuropathological damages in 
both in vivo and in vitro models of PD [60, 61]. Apocynin also 
slowed disease progression and extended survival in a mouse ALS 
model [62]. There has clearly been some experience with apocy-
nin in humans, considering the long history of its use in Eastern 
medicine, but a handful of studies in humans have been reported 
in unrelated conditions such as nebulized apocynin in asthmatics 
[63, 64]. Under these circumstances, apocynin appears to be well 
tolerated clinically, but more work is still needed.
Honokiol and plumbagin
Other natural compounds of NOX inhibitor are honokiol and 
plumbagin. Honokiol was isolated from the herb Magnolia offi-
cinalis and has been of particular interest because this compound 
appears to inhibit superoxide production after the respiratory 
burst and not before the enzyme is activated as with other inhibi-
tors [65]. Honokiol has also been shown to lesion size in experi-
mental ischemic stroke followed by reperfusion and this decrease 
was correlated to a reduction in neutrophil infiltration and activa-
tion, and decreased lipid peroxidation [65, 66]. The only inhibitor 
to date that directly interacts with a specific NOX homolog seems 
to be a plant derived naphthoquinone called plumbagin [67]. 
Fig. 3. The mechanism of inhibition of 
apocynin on NOX-induced superoxide pro-
duction. In neutrophil, dimerized apocynin 
by MPO and H2O2 prevents assembly of an 
intact enzyme complex by preventing the 
association of cytosolic subunit p47 with the 
membrane subunit gp91. In vascular cell, 
apocynin could also be dimerized by MPO 
secreted from neutroophils. It inhibits vas-
cular NOX, which is composed of NOX2 or 
its homologues (NOX1, NOX4, or NOX5) as 
the catalytic subunit. (Apo: Apocynin)
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Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a natu-
ral yellow pigment that comes from the roots of the black walnut 
plant Plumbago zeylanica. Plumbagin inhibits non-phagocytic 
NOX activity in HEK293 and LN229, a cell line that only express 
NOX4 and in a cell line transfected for NOX4 [67]. The regulation 
of NOX4 appears to be different from the other NOX homologs 
which require p47phox and p67phox, and it has been observed that 
NOX4 alone can produce superoxide activity [68-70]. The method 
by which it inhibits NOX4 is unknown but it is unlikely that it is 
due to cytotoxic effects as the cells were viable after 1 hour incuba-
tion with plumbagin [67]. It has been shown to have significant 
anti-cancer activity and may work by blocking superoxide produc-
tion as many cancers have been shown to produce ROS and spe-
cifically express NOX homologs [71-74]. NOX4 is the dominant 
NOX homolog in vascular smooth muscle cells and its inhibition 
by plumbagin may well explain its anti-atheroscerotic effect. 
Gp91ds-tat
The most selective NOX inhibitor to date is a chimeric peptide 
gp91ds-tat [75]. This peptide is constructed from the sequence of 
gp91phox that is known to be involved in the binding of gp91phox to 
p47phox and can inhibit the oxygen radical production in cell-free 
assays (gp91 docking sequence or gp91ds). In order to deliver this 
peptide into the cells, the gp91ds was linked to HIV coat peptide 
(HIVtat) that is known to be involved in internalization [75]. This 
gp91ds-tat specifically binds to p47phox and prevents the formation 
of the NOX complex. While this is the most specific inhibitor for 
NOX, it cannot distinguish between the phagocytic or non-phago-
cytic enzyme and it has little oral bioavailability as it is a peptide. 
Serine protease inhibitors
One of a group of NOX inhibitors is the 4-(2-aminoethyl)-
benzenesulfonyl fluoride (AEBSF) which an irreversible serine 
protease inhibitor [76]. AEBSF appears to have a direct effect on 
the plasma membrane components of NOX and interrupt with the 
binding of the cytosolic components p47phox and p67phox. AEBSF 
does not interfere with the electron transport and does not scav-
enge the oxygen radicals. Unfortunately, AEBSF modifies many 
proteins by covalent attachment preferentially on tyrosine, and to 
a lesser extent on lysine, histidine, and the amino-terminus. AEBSF 
is quite stable in aqueous solution and the extent to which the 
protein is modified continues to increase for several days and this 
significantly limits its use in vivo. Tosylphenylalanychloromethane 
is another irreversible serine protease inhibitor similar to AEBSF 
and has a similar mechanism of action [77]. However, no studies to 
date have been carried out in stroke models of these compounds.
Phenylarsine oxide and gliotoxin
Other NOX inhibitors include phenylarsine oxide and gliotoxin 
[78]. Phenylarsine oxide, via its interaction with cysteine residues, 
appears to prevent NADPH enzyme assembly. However, this 
inhibitor is quite non-specific. Due to its interactions with the cys-
teine groups it will also interact with other enzymes and proteins 
[79, 80]. Gliotoxin is extracted from Aspergillus and it appears to 
inhibit the enzyme by blocking the phosphorylation of p47phox [53, 
81]. It also seems to react with the thiol groups, thus limiting its 
specificity. To date, there do not appear to be any studies examin-
ing the therapeutic value of these compounds in stroke or stroke 
models.
Ebselen
There are NOX inhibitors that have either been specifically de-
veloped by the pharmaceutical industry or are in clinical trials. 
Ebselen, 2-phenyl-1,2-benzisoselenazol-3(2H)-one, a mimic of 
glutathione peroxidase which also reacts with peroxynitrite, in-
hibits a variety of enzymes such as lipoxygenases, nitric oxide syn-
thases, NOX, protein kinase C, and Hz/Kz-ATPase [82]. Ebselen 
is therefore quite non-specific, but is being used at some centers 
for the treatment of stroke in Japan. Ebselen has shown efficacy if 
the treatment is started within 24 hours of the stroke [83, 84]. Cur-
rently, a multicenter phase 3 ebselen trial is ongoing (www.stroke-
center.org). 
VAS2870
A few other inhibitors have been developed by the pharma-
ceutical industry including VAS2870 (Vasopharm) [56, 85]. The 
VAS2870 has been shown to be neuroprotective in preclinical 
stroke experiments [56]. It appears to a more specific to inhibitor 
of all NOX isoforms, and is neither general flavoprotein inhibitor 
nor ROS scavengers [85, 86]. VAS2879 appears to be a pan-NOX 
inhibitor, as it prevents assembly or conformational change to ac-
tive NOX complexes [87, 88]. When VAS2870 was admitted before 
complex assembly induction, it inhibited a NOX2 activity [87]. 
Therefore, the order by which a NOX complex assembly activa-
tor and a NOX inhibitor are added in cell-free assays is crucial. A 
recent study showed that VAS2870 has potential off-target effects, 
suggesting that the compound alkylates cysteine thiol residues [89]. 
To date, there has been only one study examining this compound 
in a stroke model [56]. In this study, VAS2870 treatment led to 
superior lesion size reduction and improvement in neurological 
deficits compared to no treatment.
HMGCoA reductase inhibitors
Finally, angiotensin converting enzyme (ACE) inhibitors, angio-
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tensin receptor-1 blockers (ARBs), and the HMGCoA reductase 
inhibitor (statins) drugs can all indirectly inhibit NOX activity 
[86, 90]. Statins, ACE inhibitors and ARBs have all been shown to 
protect the brain from experimental stroke for various reasons. In 
particular, statins have been shown to improve outcome from ex-
perimental stroke via their ability to upregulate endothelial nitric 
oxide synthase [91]. All of these compounds have been shown to 
correlate to an anti-inflammatory effect, although whether this is 
directly due to NOX inhibition seems less likely, with these com-
pounds acting as a related immune target.
CONCLUSION
In conclusion, NOX appear to an important player in ischemic 
stroke, particularly as it relates to reperfusion injury due to its gen-
eration of superoxide. Superoxide is well known to contribute to 
the progression of stroke and related cerebrovascular diseases as 
well as neurodegenerative conditions. By inhibiting NOX, several 
preclinical studies have reported improved neurological outcome, 
and reduced severity of brain injury including brain hemorrhage. 
While available inhibitors may be non-specific or have a relatively 
narrow therapeutic window, we suggest that it is still worthwhile 
to investigate NOX inhibitors, and to carry out studies to develop 
safe and selective drugs for treatment of clinical stroke, its compli-
cations and for related conditions as well. Further, there is rapidly 
increasing knowledge of the role of the various NOX isoforms. 
Whether one form versus another is relevant to one type of pa-
thology compared to another is still unknown. Such knowledge 
could also drive the development of appropriate therapies as well. 
Clearly, several laboratory and preclinical animal model studies 
have shown the salutary effects of several NOX isoforms as viable 
targets for treatment of ischemic stroke. While limiting elabora-
tion of damaging ROS into the ischemic brain during reperfusion, 
its inhibition leads to the inhibition of the local inflammatory 
response and, as a result, may prevent secondary complications 
of stroke such as BBB disruption and brain hemorrhage. Since 
reperfusion injury, including hemorrhagic transformation and the 
development of a frank parenchymal hematoma, are significant 
complications of thrombolysis, NOX inhibitors have the potential 
to be used in conjunction with recombinant tissue plasminogen 
activator (rt-PA), in addition to being used as a stand alone neuro-
protectant. However, pharmacological development of a specific 
and safe inhibitor is still lacking. Several inhibitors have been stud-
ied by various labs and, while shown to be effective in laboratory 
models, are either non-specific in their inhibition, or may have off 
target toxicities that could limit translational development. The 
issue of specificity may not be as critical, since several NOX iso-
forms have been shown to contribute to stroke pathophysiology, 
and off target effects, such as non-specific anti-oxidant properties, 
may contribute to neuroprotection. More importantly, it will be 
important to develop therapies with less toxicity. Finally, the is-
sue of whether such compounds may pass the BBB may be less 
important compared to other therapies, since NOX is present on 
circulating leukoctyes, which could be targeted without requiring 
a NOX inhibitor to enter the brain.
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